Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

150.88
+2.641.78%
Volume:41.38K
Turnover:6.16M
Market Cap:2.17B
PE:-30.81
High:150.94
Open:148.18
Low:144.22
Close:148.24
52wk High:161.38
52wk Low:49.81
Shares:14.41M
Float Shares:8.40M
Volume Ratio:0.76
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8978
EPS(LYR):-3.7076
ROE:-46.63%
ROA:-22.05%
PB:10.02
PE(LYR):-40.69

Loading ...

Palvella Therapeutics Inc. : H.c. Wainwright Raises Target Price to $270 From $255

THOMSON REUTERS
·
Mar 24

Palvella Therapeutics to host full-year 2025 financial results conference call and corporate update

Reuters
·
Mar 24

Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services

Reuters
·
Mar 23

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 21

Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Mar 19

Palvella Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 17

Palvella Therapeutics Secures European Patent No. 3565520 for QTORIN Rapamycin Anhydrous Gel

Reuters
·
Mar 16

Palvella Therapeutics launches ‘BEYOND mLM’ disease awareness campaign

TIPRANKS
·
Mar 10

Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

GlobeNewswire
·
Mar 10

Palvella Therapeutics Director George M Jenkins Acquires Common Shares

Reuters
·
Mar 02

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Mar 02

BTIG Remains a Buy on Palvella Therapeutics (PVLA)

TIPRANKS
·
Mar 02

Palvella Therapeutics price target raised to $220 from $200 at Chardan

TIPRANKS
·
Mar 02

Palvella Therapeutics (PVLA) Receives a Buy from Clear Street

TIPRANKS
·
Mar 02

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)

TIPRANKS
·
Feb 28

Palvella Therapeutics Announces Underwritten Common Stock Offering

TIPRANKS
·
Feb 27

Top Midday Gainers

MT Newswires Live
·
Feb 27

Assessing Palvella Therapeutics (PVLA) Valuation After Its Recent Share Price Surge

Simply Wall St.
·
Feb 26

Palvella Therapeutics 1.6M share Secondary priced at $125.00

TIPRANKS
·
Feb 26

BRIEF-Palvella Therapeutics Announces Pricing Of Upsized Public Offering

Reuters
·
Feb 26